Doctors facing grim choice over ventilators told to put patients with disabilities at the back of the line
By Deborah Hellman,
The Conversation
| 04. 20. 2020
In several states, existing policies that were developed in anticipation of an emergency – including pandemics – recommend rationing that prioritizes giving ventilators to otherwise healthy people who are most likely to benefit.
As cases related to the novel coronavirus continue to strain hospitals, doctors face difficult choices about rationing scarce medical resources like ventilators – choices that will likely determine who lives and who dies.
Several states’ policies tell providers to allocate scarce resources to those most likely to benefit. For example, Washington state recently adopted a policy that favors “the survival of young otherwise healthy patients more heavily than that of older, chronically debilitated patients.” Similar new guidelines have been issued in Massachusetts as well.
In several other states, existing policies that were developed in anticipation of an emergency – including pandemics – recommend rationing that prioritizes giving ventilators to otherwise healthy people who are most likely to benefit. The policies may be mandatory in some contexts, depending on state law, but are likely to be influential even when not required.
While seemingly sensible, policies that focus exclusively on saving as many lives as possible may miss something just as important about whose life is spared and whose is not.
As a scholar who studies the law and ethics of discrimination...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi, MIT Technology Review | 03.25.2025
Why do we hear about medical breakthroughs in mice, but rarely see them translate into cures for human disease? Why do so few drugs that enter clinical trials receive regulatory approval? And why is the waiting list for organ transplantation...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...